270 related articles for article (PubMed ID: 25897673)
1. Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone.
Salvi S; Casadio V; Conteduca V; Burgio SL; Menna C; Bianchi E; Rossi L; Carretta E; Masini C; Amadori D; Calistri D; Attard G; De Giorgi U
Br J Cancer; 2015 May; 112(10):1717-24. PubMed ID: 25897673
[TBL] [Abstract][Full Text] [Related]
2. AR-V7 in Peripheral Whole Blood of Patients with Castration-resistant Prostate Cancer: Association with Treatment-specific Outcome Under Abiraterone and Enzalutamide.
Seitz AK; Thoene S; Bietenbeck A; Nawroth R; Tauber R; Thalgott M; Schmid S; Secci R; Retz M; Gschwend JE; Ruland J; Winter C; Heck MM
Eur Urol; 2017 Nov; 72(5):828-834. PubMed ID: 28818355
[TBL] [Abstract][Full Text] [Related]
3. Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer.
Antonarakis ES; Lu C; Luber B; Wang H; Chen Y; Nakazawa M; Nadal R; Paller CJ; Denmeade SR; Carducci MA; Eisenberger MA; Luo J
JAMA Oncol; 2015 Aug; 1(5):582-91. PubMed ID: 26181238
[TBL] [Abstract][Full Text] [Related]
4. Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study.
Conteduca V; Wetterskog D; Sharabiani MTA; Grande E; Fernandez-Perez MP; Jayaram A; Salvi S; Castellano D; Romanel A; Lolli C; Casadio V; Gurioli G; Amadori D; Font A; Vazquez-Estevez S; González Del Alba A; Mellado B; Fernandez-Calvo O; Méndez-Vidal MJ; Climent MA; Duran I; Gallardo E; Rodriguez A; Santander C; Sáez MI; Puente J; Gasi Tandefelt D; Wingate A; Dearnaley D; ; ; Demichelis F; De Giorgi U; Gonzalez-Billalabeitia E; Attard G
Ann Oncol; 2017 Jul; 28(7):1508-1516. PubMed ID: 28472366
[TBL] [Abstract][Full Text] [Related]
5. Testosterone levels and androgen receptor copy number variations in castration-resistant prostate cancer treated with abiraterone or enzalutamide.
Lolli C; De Lisi D; Conteduca V; Gurioli G; Scarpi E; Schepisi G; Ravaglia G; Menna C; Farolfi A; Altavilla A; Burgio SL; Tonini G; Santini D; De Giorgi U
Prostate; 2019 Aug; 79(11):1211-1220. PubMed ID: 31251826
[TBL] [Abstract][Full Text] [Related]
6. CYP17A1 polymorphism c.-362T>C predicts clinical outcome in metastatic castration-resistance prostate cancer patients treated with abiraterone.
Crucitta S; Del Re M; Paolieri F; Bloise F; Sbrana A; Sammarco E; Mercinelli C; Cucchiara F; Fontanelli L; Galli L; Danesi R
Cancer Chemother Pharmacol; 2020 Oct; 86(4):527-533. PubMed ID: 32945940
[TBL] [Abstract][Full Text] [Related]
7. Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide.
Antonarakis ES; Lu C; Luber B; Wang H; Chen Y; Zhu Y; Silberstein JL; Taylor MN; Maughan BL; Denmeade SR; Pienta KJ; Paller CJ; Carducci MA; Eisenberger MA; Luo J
J Clin Oncol; 2017 Jul; 35(19):2149-2156. PubMed ID: 28384066
[TBL] [Abstract][Full Text] [Related]
8. AR-V7 Transcripts in Whole Blood RNA of Patients with Metastatic Castration Resistant Prostate Cancer Correlate with Response to Abiraterone Acetate.
Todenhöfer T; Azad A; Stewart C; Gao J; Eigl BJ; Gleave ME; Joshua AM; Black PC; Chi KN
J Urol; 2017 Jan; 197(1):135-142. PubMed ID: 27436429
[TBL] [Abstract][Full Text] [Related]
9. Prognostic and Therapeutic Implications of Circulating Androgen Receptor Gene Copy Number in Prostate Cancer Patients Using Droplet Digital Polymerase Chain Reaction.
Buelens S; Claeys T; Dhondt B; Poelaert F; Vynck M; Yigit N; Thas O; Ost P; Vandesompele J; Lumen N; Kumps C
Clin Genitourin Cancer; 2018 Jun; 16(3):197-205.e5. PubMed ID: 29366632
[TBL] [Abstract][Full Text] [Related]
10. Androgen receptor gain in circulating free DNA and splicing variant 7 in exosomes predict clinical outcome in CRPC patients treated with abiraterone and enzalutamide.
Del Re M; Conteduca V; Crucitta S; Gurioli G; Casadei C; Restante G; Schepisi G; Lolli C; Cucchiara F; Danesi R; De Giorgi U
Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):524-531. PubMed ID: 33500577
[TBL] [Abstract][Full Text] [Related]
11. Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer.
Azad AA; Volik SV; Wyatt AW; Haegert A; Le Bihan S; Bell RH; Anderson SA; McConeghy B; Shukin R; Bazov J; Youngren J; Paris P; Thomas G; Small EJ; Wang Y; Gleave ME; Collins CC; Chi KN
Clin Cancer Res; 2015 May; 21(10):2315-24. PubMed ID: 25712683
[TBL] [Abstract][Full Text] [Related]
12. Plasma AR and abiraterone-resistant prostate cancer.
Romanel A; Gasi Tandefelt D; Conteduca V; Jayaram A; Casiraghi N; Wetterskog D; Salvi S; Amadori D; Zafeiriou Z; Rescigno P; Bianchini D; Gurioli G; Casadio V; Carreira S; Goodall J; Wingate A; Ferraldeschi R; Tunariu N; Flohr P; De Giorgi U; de Bono JS; Demichelis F; Attard G
Sci Transl Med; 2015 Nov; 7(312):312re10. PubMed ID: 26537258
[TBL] [Abstract][Full Text] [Related]
13. CYP17A1 polymorphisms and clinical outcome of castration-resistant prostate cancer patients treated with abiraterone.
Salvi S; Casadio V; Burgio SL; Conteduca V; Rossi L; Menna C; Carretta E; Costantini M; Zoli W; De Giorgi U
Int J Biol Markers; 2016 Jul; 31(3):e264-9. PubMed ID: 26954071
[TBL] [Abstract][Full Text] [Related]
14. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors.
Chen EJ; Sowalsky AG; Gao S; Cai C; Voznesensky O; Schaefer R; Loda M; True LD; Ye H; Troncoso P; Lis RL; Kantoff PW; Montgomery RB; Nelson PS; Bubley GJ; Balk SP; Taplin ME
Clin Cancer Res; 2015 Mar; 21(6):1273-80. PubMed ID: 25320358
[TBL] [Abstract][Full Text] [Related]
15. Abiraterone switches castration-resistant prostate cancer dependency from adrenal androgens towards androgen receptor variants and glucocorticoid receptor signalling.
Moll JM; Hofland J; Teubel WJ; de Ridder CMA; Taylor AE; Graeser R; Arlt W; Jenster GW; van Weerden WM
Prostate; 2022 Apr; 82(5):505-516. PubMed ID: 35037287
[TBL] [Abstract][Full Text] [Related]
16. Circulating androgen receptor combined with 18F-fluorocholine PET/CT metabolic activity and outcome to androgen receptor signalling-directed therapies in castration-resistant prostate cancer.
Conteduca V; Scarpi E; Caroli P; Salvi S; Lolli C; Burgio SL; Menna C; Schepisi G; Testoni S; Gurioli G; Paganelli G; Casadio V; Matteucci F; De Giorgi U
Sci Rep; 2017 Nov; 7(1):15541. PubMed ID: 29138500
[TBL] [Abstract][Full Text] [Related]
17. Enzalutamide Antitumour Activity Against Metastatic Castration-resistant Prostate Cancer Previously Treated with Docetaxel and Abiraterone: A Multicentre Analysis.
Brasso K; Thomsen FB; Schrader AJ; Schmid SC; Lorente D; Retz M; Merseburger AS; von Klot CA; Boegemann M; de Bono J
Eur Urol; 2015 Aug; 68(2):317-24. PubMed ID: 25108579
[TBL] [Abstract][Full Text] [Related]
18. Circulating AR copy number and outcome to enzalutamide in docetaxel-treated metastatic castration-resistant prostate cancer.
Salvi S; Casadio V; Conteduca V; Lolli C; Gurioli G; Martignano F; Schepisi G; Testoni S; Scarpi E; Amadori D; Calistri D; Attard G; De Giorgi U
Oncotarget; 2016 Jun; 7(25):37839-37845. PubMed ID: 27191887
[TBL] [Abstract][Full Text] [Related]
19. Circulating-tumor DNA as predictor of enzalutamide response post-abiraterone treatment in metastatic castration-resistant prostate cancer.
Moses M; Niu A; Lilly MB; Hahn AW; Nussenzveig R; Ledet E; Manogue C; Cotogno P; Lewis B; Layton J; Agarwal N; Sartor O; Barata PC
Cancer Treat Res Commun; 2020; 24():100193. PubMed ID: 32702615
[TBL] [Abstract][Full Text] [Related]
20. Association of AR-V7 and Prostate-Specific Antigen RNA Levels in Blood with Efficacy of Abiraterone Acetate and Enzalutamide Treatment in Men with Prostate Cancer.
Qu F; Xie W; Nakabayashi M; Zhang H; Jeong SH; Wang X; Komura K; Sweeney CJ; Sartor O; Lee GM; Kantoff PW
Clin Cancer Res; 2017 Feb; 23(3):726-734. PubMed ID: 27489290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]